Up to $20,000 available to the digital health company that solves one of the challenges proposed by MSD
- Details
- Category: Business
MSD is looking for innovators to solve 7 health-related challenges aiming to support physician education or patient disease management. The 3 digital solutions with the most outstanding value will receive up to $20,000 each to be launched in a local market. MSD will also work side by side with the winning solvers to facilitate the roll-out of their solution.
Daiichi Sankyo announces TaNeDS Global 2018 collaborative drug discovery program
- Details
- Category: Daiichi Sankyo
Daiichi Sankyo Company, Limited today announced details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Global 2018, a collaborative drug discovery initiative for universities and research institutes in Europe and the East Coast of the United States.
Bevespi Aerosphere demonstrates statistically significant improvement in lung function in patients with COPD
- Details
- Category: AstraZeneca
AstraZeneca today announced positive top-line results of the Phase III, PINNACLE 4 trial in which Bevespi Aerosphere* (glycopyrronium and formoterol fumarate 14.4/9.6 µg) demonstrated a statistically significant improvement in lung function as measured by trough forced expiratory volume in one second (FEV1), compared to its monotherapy components (glycopyrronium 14.4 µg and formoterol fumarate 9.6 µg) and placebo,
Amgen Foundation pledges up to $5 million to Hurricane Maria relief efforts
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) announced that the Amgen Foundation has pledged $3 million to support urgent Hurricane Maria relief efforts in Puerto Rico. The Foundation also has committed up to an additional $2 million for longer-term rebuilding efforts. Amgen is also activating its Staff Disaster Relief Fund to aid Amgen staff in Puerto Rico, including financial assistance for shelter, medical attention, clothing and other critical relief.
AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors
- Details
- Category: Bristol-Myers Squibb
AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
- Details
- Category: Novartis
Novartis announced a new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML), gastrointestinal tumors (GIST) and other rare cancers. The two organizations have been long-time collaborators in providing access to care for patients in lower-income countries through the Glivec International Patient Assistance Program (GIPAP),
New scholarships worth EUR 417,000 awarded by Bayer Foundation to promote international talents
- Details
- Category: Bayer
With approximately EUR 417,000, the Bayer Science & Education Foundation is providing a record amount for 65 talented young people who wish to realize international study and vocational training projects. The new scholarship recipients are students of the natural sciences, agriculture and medicine, as well those training to become science teachers or young people from skilled non-academic professions.
More Pharma News ...
- Pfizer goes to Court to allow competition for biologics and expand options for patients
- IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to 'listen for the sounds of IPF'
- Johnson & Johnson announces collaboration with U.S. Department of Health and Human Services to fight influenza
- Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
- Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for ENHANZE technology
- More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments
- AstraZeneca presents new results identifying severe asthma patients who would benefit most from benralizumab